Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Apoptosis

NEW YORK, May 3, 2011 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:

Triple Analysis: Colorectal Cancer, Leukemia and
Apoptosis

http://www.reportlinker.com/p0284934/Triple-Analysis-Colorectal-Cancer-Leukemia-and-Apoptosis.html

This triple analysis focuses on cancer drug development
strategies in both Colorectal Cancer and Leukemia and by the
mechanism/target/effect of Apoptosis. Each of these three
individual parts is evaluated according to standardized criteria in
a five pillar pipeline drug assessment methodology to compare drug
development strategies in oncology. This makes it easy to find and
compare analysis not only within one single cancer focus area but
also between different areas.

Below is a short synopsis of each part included in this
report:

Part I: Colorectal Cancer

The colorectal cancer report part comprises defined and up to
date development strategies for 347 colorectal cancer drugs within
the portfolio of 182 investigators, from Ceased to Marketed. This
part extensively analyses their 210 identified drug targets,
organized into 205 drug target strategies, and assesses them in
eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer
Pipeline: From Research and Development to Market

Part II: Leukemia

The leukemia report part comprises defined and up to date
development strategies for 313 leukemia drugs within the portfolio
of 186 investigators, from Ceased to Marketed. This part
extensively anal

‘/>”/>

SOURCE